Find Clinical Trials

On this page, you will find different kinds of study results:

• A Lay summary which is a summary of clinical trial results written in an easy-to-understand way.
• A summary of results called synopsis which is written in scientific language. It is prepared for Medicines Agencies and Ethics Committees,
• A scientific publication which presents results for scientists and medical doctors.

213 Results

Protocol Code	Study Title	Active substance/Medical device	Study Phase	Therapeutic Area
PKH-05720-001	A study to assess the release profiles from fixed combination tablets (gliclazide MR/metformin)	GLICLAZIDE, METFORMINE, S005720	Phase 1	Metabolism
MC3-06790-001	Study of the effect of trimetazidine MR 35 mg (2 tabs/day) on the emergence of…	TRIMETAZIDINE, S006790	Phase 3	Other
IC4-5702-205-CHN	Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat…	GLICLAZIDE, S005702	Phase 4	Metabolism
IC4-20098-542	Efficacy and safety of Valdoxan® given orally once a day for 24 weeks in patients…	AGOMELATINE, S020098	Phase 4	Neuropsychiatric Diseases
IC4-12911-098	PRotelos 2g in the OSteoporosis treatment, the Tolerability and Efficacy Profile - PROSTEP	STRONTIUM RANELATE, S012911	Phase 4	Rheumatology
IC4-05682-099	Efficacy of Detralex® in Edema Treatment. An open, 6-month, multicentre study. EDET Study	MICRONISED PURIFIED FLAVONOID FRACTION, S005682	Phase 4	Cardiovascular Diseases
IC4-05682-031	Detralex* versus placebo in the treatment of acute hemorrhoids in patients with acute hemorrhoidal attack.…	MICRONISED PURIFIED FLAVONOID FRACTION, S005682	Phase 4	Cardiovascular Diseases
DM4-90652-001	Patient pREference and satisFaction for pErindopril oRodispersible vs convENtional tablets in daily Clinical practicE. PREFERENCE	PERINDOPRIL ARGININE, S090652	Phase 4	Cardiovascular Diseases
DM4-20098-112	Clinical long-term effects of Valdoxan® (25 or 50 mg) in depressed patients. Clinical, national, interventional,…	AGOMELATINE, S020098	Phase 4	Neuropsychiatric Diseases
DM4-20098-108	Clinical efficacy of VALDOXAN in everyday practice conditions (efficiency) in depressed patients, on a treatment-naive…	AGOMELATINE, S020098	Phase 4	Neuropsychiatric Diseases
DM4-20098-107	Response to VALDOXAN® and restoration of social rhythms in Major Depressive Disorder: VALDOXAN® D-Rhythm study.…	AGOMELATINE, S020098	Phase 4	Neuropsychiatric Diseases
CL3-95005-004	Update in progress An open-label early access phase IIIb study of trifluridine / tipiracil (S 95005/TAS-102) in patients…	TIPIRACIL, TRIFLURIDINE, S095005	Phase 3	Cancers
CL3-90652-004	Evaluation of the effect of the oral administration of perindopril orodispersible at a dose of…	PERINDOPRIL ARGININE, S090652	Phase 3	Cardiovascular Diseases
CL3-78989-019	A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis…	GEVOKIZUMAB, S078989	Phase 3	Other
CL3-78989-002	A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients…	GEVOKIZUMAB, S078989	Phase 3	Other
CL3-20098-089	Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day…	AGOMELATINE, S020098	Phase 3	Neuropsychiatric Diseases
CL3-20098-087	Efficacy and safety of 2 doses of agomelatine (10 mg/day or 25 mg/day) versus placebo…	AGOMELATINE, S020098	Phase 3	Neuropsychiatric Diseases
CL3-20098-083	Early effect of agomelatine on general interest in outpatients with Major Depressive Disorder. A 12-week,…	AGOMELATINE, S020098	Phase 3	Neuropsychiatric Diseases
CL3-20098-080	Effects of agomelatine (25 to 50 mg/day) on circadian rhythms in patients with Major Depressive…	AGOMELATINE, S020098	Phase 3	Neuropsychiatric Diseases
CL3-20098-078	Efficacy and safety of agomelatine (25-50 mg/day) for 12 weeks in patients with Generalized Anxiety…	AGOMELATINE, S020098	Phase 3	Neuropsychiatric Diseases
CL3-20098-076	Efficacy and safety of 2 doses of agomelatine (10mg, 25mg) given orally in children (from…	AGOMELATINE, S020098	Phase 3	Neuropsychiatric Diseases
CL3-20098-074	Efficacy and safety of agomelatine with flexible dose (25 mg/day with blinded potential adjustment at…	AGOMELATINE, S020098	Phase 3	Neuropsychiatric Diseases
CL3-20098-073	Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering Major Depressive…	AGOMELATINE, S020098	Phase 3	Neuropsychiatric Diseases
CL3-20098-071	Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for…	AGOMELATINE, S020098	Phase 3	Neuropsychiatric Diseases
CL3-20098-070	Efficacy and safety of agomelatine oral administration (25 to 50 mg/day) in elderly patients suffering…	AGOMELATINE, S020098	Phase 3	Neuropsychiatric Diseases

Previous 1 2 3 4 … 8 9 Next